Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “While we contin...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Amanita fuliginea poisoning with thrombocytopenia: a case series - Wang Q, Sun M, Lv H, Lu P, Ma C, Liu Y, Liu S, Tong H, Hu Z, Gao Y.
We present 3 cases of severe A. fuliginea poisoning associated with thrombocytopenia in China. Three patients consumed foraged A. fuliginea and developed nau... (Source: SafetyLit)
Source: SafetyLit - February 3, 2020 Category: International Medicine & Public Health Tags: Home and Consumer Product Safety Source Type: news
Severe Thrombocytopenia in a Patient With Lung Adenocarcinoma Severe Thrombocytopenia in a Patient With Lung Adenocarcinoma
This case of severe grade V thrombocytopenia caused by nivolumab highlights the need for clinicians to be aware of this potential adverse effect of immune-checkpoint inhibitors.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 14, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Dova Granted Orphan Drug Designation for Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia
DURHAM, N.C., Jan. 13, 2020 -- (Healthcare Sales & Marketing Network) -- Dova Pharmaceuticals, Inc., a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi), has been granted Orphan Drug Designation1 (ODD) by the US Food and Drug Administr... Biopharmaceuticals, Oncology, FDA Dova Pharmaceuticals, avatrombopag, Chemotherapy-Induced, Thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 13, 2020 Category: Pharmaceuticals Source Type: news
Avatrombopag cost effective for thrombocytopenia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 31, 2019 Category: Drugs & Pharmacology Source Type: news
Romiplostim for Chemotherapy-Induced Thrombocytopenia Romiplostim for Chemotherapy-Induced Thrombocytopenia
Does the thrombopoietin receptor agonist romiplostim expedite correction of thrombocytopenia caused by chemotherapy?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 11, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
How Does Gaucher Disease Present?
Discussion
Gaucher disease (GD) was first described by Philippe Gaucher in 1882. It was the first lysosomal storage disease (LSD) described and is the comparison prototype for many variations and their treatment. There are about 50 LSD and more well-known ones include Fabry, Niemann-Pick and Pompe diseases. LSDs currently have more than 300 different enzymes or membrane proteins affected which cause central nervous system and visceral disease. Overall the frequency of LSDs in aggregate is 1:3000 – 7000 live births. GD has an estimated prevalence of 1:57,000 – 111,000. It is higher within the Ashkenazi Jewish po...
Source: PediatricEducation.org - December 9, 2019 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
EMA Panel Backs Fostamatinib (Tavalisse) for Chronic ITP EMA Panel Backs Fostamatinib (Tavalisse) for Chronic ITP
Fostamatinib, a spleen tyrosine kinase inhibitor, helps increase and maintain the platelet count and reduce bleeding risk in adults with chronic immune thrombocytopenia refractory to other treatments.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 15, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2019 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Med... Biopharmaceuticals, Regulatory Rigel Pharmaceuticals, fostamatinib, immune thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 15, 2019 Category: Pharmaceuticals Source Type: news
Nplate ® (romiplostim) now approved for earlier use in adults with immune thrombocytopenia
Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) to include new data in its U.S. prescribing information showing sustained platelet responses in adults with immune thrombocytopenia (ITP), a rare, serious autoimmune disease characterized by low platelet counts. (Source: World Pharma News)
Source: World Pharma News - October 21, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news
Nplate(R) (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
32% of Patients Achieved Treatment-Free Remission for at Least Six Months in a Single-Arm Trial
93% of Patients Achieved a Platelet Response
THOUSAND OAKS, Calif., Oct. 18, 2019 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ:AMGN) today ... Biopharmaceuticals, FDA Amgen, Nplate, romiplostim, Immune Thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 18, 2019 Category: Pharmaceuticals Source Type: news
Nplate (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
THOUSAND OAKS, Calif., Oct. 18, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved Amgen ' s Supplemental Biologics License Application (sBLA) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 18, 2019 Category: Drugs & Pharmacology Source Type: news
Sobi to Acquire Dova Pharmaceuticals Creating a Global Growth Platform in Haematology
The acquisition of Dova provides Sobi with Doptelet (avatrombopag), a differentiated on-market product in Chronic Immune Thrombocytopenia (ITP), a well established and growing market, for Chronic Liver Disease (CLD) and an ongoing phase 3 trial in Chemothe... Biopharmaceuticals, Mergers & Acquisitions Swedish Orphan Biovitrum, Sobi , Dova Pharmaceuticals (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 30, 2019 Category: Pharmaceuticals Source Type: news
MPV, PDW, and PLT Count in ITP and Essential Thrombocytopenia MPV, PDW, and PLT Count in ITP and Essential Thrombocytopenia
This study analyzed and compared MPV and PDW values in immune thrombocytopenic purpura and essential thrombocythemia. How do they compare with values in healthy individuals?Laboratory Medicine (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - August 27, 2019 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news
The Dengue Dance?
Discussion
Dengue is an important arboviral infection that affects about 40% of the world population. It is found mainly in topical and subtropical areas of the world mainly in developing countries but it range is spreading including the United States. A review of common arboviruses can be found here. It is a flaviavirus with 4 distinct serotypes named DENV-1 through DENV-4 and is spread by A. aegypti a day biting mosquito. Infection with one serotype confers immunity to that serotype but not the others. It does offer some protection for cross-infection but this only lasts a few months. Incubation period is 3-14 days with ...
Source: PediatricEducation.org - July 29, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
